Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Pharmaceutical Investing
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers Life Science Investing
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Life Science Investing
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH Life Science Investing
Agility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial Officer Life Science Investing
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 Life Science Investing
Ciprocopan Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Life Science Investing
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency in Late-Breaking Oral Presentation at the European Respiratory Society Congress 2026 Life Science Investing
